收藏产品 产品信息
分子别名（Synonym）
MS4A1,CD20,MS4A-1
表达区间及表达系统（Source）
Human CD20 Full Length Protein, His Tag (CD0-H52H3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
Predicted N-terminus: Met 1
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>85% as determined by SDS-PAGE.
制剂（Formulation）
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
产品数据图
电泳（SDS-PAGE）
Human CD20 Full Length Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).
活性（Bioactivity）-ELISA
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with a linear range of 0.4-3 ng/mL (in presence of DDM and CHS) (QC tested).
Protocol
Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with a linear range of 0.4-6 ng/mL (in presence of DDM and CHS) (QC tested).
Protocol
Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 0.3-5 ng/mL (Routinely tested).
Protocol
Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3 at 1 μg/mL, add Glofitamab and then add Biotinylated Human CD3E&CD3G Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDG-H82W3) at 1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Protocol
活性（Bioactivity）-SPR
MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 6.21 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (QC tested).
Protocol
Ofatumumab captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 9.63 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (QC tested).
Protocol
Biosimilar of Obinutuzumab captured on CM5 chip via anti-human IgG Fc antibody can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 21.5 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Protocol
Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) captured on CM5 chip via Anti-His antibody can bind MabThera® (Rituximab) with an affinity constant of 0.921 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
活性（Bioactivity）-BLI
Loaded Rituximab on AHC Biosensor, can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 1.14 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Ofatumumab (Human IgG1) on AHC Biosensor, can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 0.968 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
产品评论 发表评论
背景
B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
靶点信息 
数据表和文档 
联系我们 
项目合作